The Selution SLR sirolimus-eluting balloon (SEB) with a higher sirolimus dosage (3 µ/mm2) demonstrated safety and efficacy in the treatment of de novo and restenotic coronary lesions, with no major adverse cardiac events (MACE) recorded through 1-year follow-up, according to results of a first-in-human study of the device.